The SNS Insider report reveals that the Nucleic Acid-based Therapeutics market, valued at USD 5.36 billion in 2023, is projected to soar to USD 14.25 billion by 2031, registering a CAGR of 13.5% over the forecast period of 2024-2031.
The surge in healthcare investments has propelled research into treatments for a wide range of diseases and disorders.
The rising prevalence of chronic and genetic conditions has amplified the need for innovative therapies, with NATs offering targeted and effective solutions. The COVID-19 pandemic further accelerated the market, showcasing the potential of mRNA vaccines and boosting confidence in nucleic acid-based approaches.
RNA-targeted therapies, ASOs (antisense oligonucleotides), and siRNAs (short interfering RNA) have garnered approvals for indications like muscular atrophy, solidifying the growing acceptance of NATs. Additionally, the expanding knowledge of the human genome has paved the way for gene therapies such as Kymriah, Yescarta, and Tecartus, transforming the treatment landscape for leukemia and lymphoma. Advancements in epigenetics research, CRISPR/Cas9 gene editing technology, and delivery mechanisms like LNPs and AAV vectors are opening new avenues for therapeutic interventions. These innovations have attracted substantial investments from companies eager to harness the potential of NATs.
The NAT market thrives on strategic collaborations, acquisitions, and partnerships.
- In August 2022, Merck & Co. partnered with Orna Therapeutics to develop RNA-based therapeutics for vaccines, infectious diseases, and oncology.
Get a Report Sample of Nucleic Acid-based Therapeutics Market @ https://www.snsinsider.com/sample-request/2762
Some of the Key Players Included are:
The Key Players are Silence Therapeutics plc, Ionis Pharmaceuticals, Novartis, Merck, Arrowhead Pharmaceuticals, BioNtech, Pfizer Inc, Protagonist Therapeutics, Inc, Biomedica, Moderna Inc., and Alnylam Pharmaceuticals, Inc. & Other Players.
Recent Developments
- In March 2023, Ionis Pharmaceuticalreceived a positive recommendation from the FDA advisory committee for the accelerated approval of Tofersen for SOD1-ALS, an antisense oligonucleotide targeting the SOD1 gene.
- In February 2023, Myeloid Therapeutics Inc.collaborated with the New South Wales Government in Australia to establish a state-of-the-art GMP manufacturing facility dedicated to RNA immunotherapies.
Segment Analysis
By Technology, RNA-targeted therapeutics dominated the market in 2023, primarily due to their versatility in targeting various genetic pathways and the success of mRNA vaccines in combating the COVID-19 pandemic. By End-user, Hospitals and clinics are the major end-users of NATs, although the market is witnessing a growing trend toward home-based administration for certain therapies.
By Technology:
- RNA-targeted therapeutics
- Gene therapies
- Epigenetic and microRNA modulating therapies
- Genome editing therapies
- Others
By End-user:
- Hospitals & Clinics
- Academic & Research Institutes
- Others
By Application:
- Autoimmune Disorders
- Infectious Diseases
- Genetic Disorders
- Cancer
- Others
Impact of Russia-Ukraine War
The ongoing conflict has disrupted global supply chains, affecting the availability of raw materials and hindering manufacturing processes. Clinical trials and research activities have been delayed or halted in the affected regions. However, the war has also spurred investments in vaccine development and highlighted the importance of preparedness for future health crises.
Make Enquiry About Nucleic Acid-based Therapeutics Market Report@ https://www.snsinsider.com/enquiry/2762
Impact of Economic Slowdown
Economic downturns often lead to reduced healthcare spending, impacting funding for research and development. Market growth may experience a temporary slowdown as consumers prioritize essential expenditures. However, the long-term potential of NATs in addressing unmet medical needs remains robust, and the market is expected to rebound as economic conditions improve.
North America dominated the Nucleic Acid-based Therapeutics market with the highest revenue share in 2023
This is driven by the high prevalence of chronic diseases, the demand for personalized medicine, and supportive government initiatives. The rising incidence of diabetes and autoimmune disorders further fuels the demand for innovative therapies.
Asia-Pacific is anticipated to witness substantial growth due to increasing awareness, medical tourism, expanding research activities, and a large, untapped population seeking quality healthcare.
Key Takeaways
- NATs are transforming medicine by offering precise and personalized treatments for genetic disorders and chronic diseases.
- Advancements in gene editing, delivery mechanisms, and omics-based research are accelerating the development of innovative NATs.
- While geopolitical events and economic fluctuations may pose challenges, the long-term potential of NATs in revolutionizing healthcare remains strong.
- In December 2022, Eli Lilly and Company and ProQR Therapeutics expanded their collaboration on RNA editing therapies.
Table of Contents – Major Key Points
- Introduction
- Research Methodology
- Market Dynamics
- Impact Analysis
- COVID-19 Impact Analysis
- Impact of Ukraine- Russia war
- Impact of ongoing Recession
- Value Chain Analysis
- Porter’s 5 Forces Model
- PEST Analysis
- Nucleic Acid-based Therapeutics Market Segmentation, By Technology
- Nucleic Acid-based Therapeutics Market Segmentation, By End-user
- Nucleic Acid-based Therapeutics Market Segmentation, By Application
- Regional Analysis
- Company Profiles
- Competitive Landscape
- Use Case and Best Practices
- Conclusion
Buy the Latest Version of Nucleic Acid-based Therapeutics Market Report 2024-2031 @ https://www.snsinsider.com/checkout/2762
About Us:
SNS Insider is one of the leading market research and consulting agencies that dominates the market research industry globally. Our company’s aim is to give clients the knowledge they require in order to function in changing circumstances. In order to give you current, accurate market data, consumer insights, and opinions so that you can make decisions with confidence, we employ a variety of techniques, including surveys, video talks, and focus groups around the world.
Contact Us:
Akash Anand – Head of Business Development & Strategy
info@snsinsider.com
Phone: +1-415-230-0044 (US) | +91-7798602273 (IND)
